29.22 0.00 (0.00%)
After hours: 5:26PM EDT
|Bid||29.26 x 3100|
|Ask||29.80 x 800|
|Day's Range||28.90 - 29.31|
|52 Week Range||20.09 - 33.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.00|
SAN DIEGO, Sept. 17, 2018-- Retrophin, Inc. today announced that the Company’ s management team will present at the following upcoming investor conferences in October:. Cantor Global Healthcare Conference ...
Retrophin, Inc. (RTRX) today announced the pricing of its offering of $240 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) to be sold in an underwritten offering. The aggregate principal amount of the offering was increased from the previously announced offering size of $200 million. Retrophin also granted the underwriters of the notes an option to purchase, for settlement on or before September 28, 2018, up to an additional $36 million aggregate principal amount of notes, solely to cover over-allotments.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...
Retrophin, Inc. (RTRX) today announced its intention to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in an underwritten offering. The notes will be senior unsecured obligations of Retrophin and will accrue interest payable semiannually in arrears. The notes will be convertible in certain circumstances into cash, shares of Retrophin’s common stock, or a combination of cash and shares of Retrophin’s common stock, at Retrophin’s election.
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of pdvWireless, ...
Evan Greebel, a former corporate lawyer found guilty last year for helping “Pharma Bro” Martin Shkreli defraud a publicly traded pharmaceutical company, was sentenced Friday by a federal judge in Brooklyn to 18 months in prison. Prosecutors from the Brooklyn U.S. Attorney’s office had sought no less than five years for Mr. Greebel, describing him as a “corrupt lawyer” who, as outside counsel to Retrophin Inc., abused his position as a lawyer to help Mr. Shkreli steal millions of dollars’ worth of cash and shares from the company to pay investors in Mr. Shkreli’s failed hedge funds. U.S. District Judge Kiyo A. Matsumoto said she believed Mr. Greebel was “personally generous and kind,” but said that he “abused his position of trust” and played an active role in the schemes.
A New York lawyer was sentenced to 18 months prison on Friday for helping Martin Shkreli, currently serving a seven year prison sentence after being convicted of related charges, defraud a drug company that Shkreli had founded. Evan Greebel, who was outside counsel to Shkreli's former company Retrophin Inc (RTRX.O), was sentenced by U.S. District Judge Kiyo Matsumoto in Brooklyn. The judge also ordered Greebel to pay about $10.4 million in restitution to Retrophin.
A New York lawyer was sentenced to 18 months prison on Friday for helping Martin Shkreli, currently serving a seven year prison sentence after being convicted of related charges, defraud a drug company that Shkreli had founded. Evan Greebel, who was outside counsel to Shkreli's former company Retrophin Inc, was sentenced by U.S. District Judge Kiyo Matsumoto in Brooklyn. The judge also ordered Greebel to pay about $10.4 million in restitution to Retrophin.
Martin Shkreli’s cohort in crime may be a "mensch" and an Eagle Scout who’s devoted his life to serving others, but that didn’t save Evan Greebel from a prison sentence for aiding the Pharma Bro in an $11 million fraud. Greebel on Friday was ordered to serve 18 months behind bars for conspiring with Shkreli, as U.S. District Judge Kiyo Matsumoto in Brooklyn, New York, turned aside his plea to remain free. "I will regret every day of my life the day that I met Martin Shkreli," Greebel told the judge.
Retrophin, Inc. (RTRX) today announced the appointment of Noah L. Rosenberg, M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline. Dr. Rosenberg brings to Retrophin more than 20 years of clinical and therapeutic development experience, including advancing several mid- and late-stage programs across therapeutic areas through to commercialization. “Noah’s expertise and career-long focus on therapeutic innovation and patient quality of care strengthens our leadership team and aligns seamlessly with our mission of identifying, developing and delivering life-changing therapies to people living with rare diseases,” said Stephen Aselage, chief executive officer of Retrophin.
Patients continue to enroll in Phase 3 FORT Study of fosmetpantotenate in PKAN and Phase 3 DUPLEX Study of sparsentan in FSGS. Phase 2 proof-of-concept study of CNSA-001 in patients with PKU set to initiate; ...
Retrophin (NASDAQ: RTRX ) announces its next round of earnings Thursday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement. Earnings and Revenue Retrophin's per-share loss ...
SAN DIEGO, July 12, 2018-- Retrophin, Inc. today announced it will report second quarter 2018 financial results on Thursday, July 26, 2018 after the close of the U.S. financial markets. The Company will ...
The San Diego-based company said it had a loss of 46 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 14 cents per share. The drug developer posted revenue of ...
New York's attorney general said state tax authorities are entitled to first dibs on more than $480,000 out of the nearly $7.4 million Shkreli was ordered to forfeit to the federal government as regulators ...